Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | MMP9 | P14780 | 2/20 | 0.42 |
| ▸ | MMP12 | P39900 | 2/20 | 0.42 |
| ▸ | KIF11 | P52732 | 4/20 | 0.39 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.36 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20528868 | 1.00 | MMP2 (0.42) | MMP2MMP9MMP12KIF11SLC6A1 | |
| SCHEMBL28959893 | 0.79 | MMP2 (0.38) | MMP2MMP9MMP12MAPT | |
| SCHEMBL28959889 | 0.78 | MEN1 (0.37) | MMP2MMP9MMP12MEN1KMT2A | |
| SCHEMBL24383273 | 0.77 | KIF11 (0.40) | MMP2MMP9MMP12KIF11SLC6A1 | |
| SCHEMBL14866488 | 0.76 | SLC6A11 (0.47) | KIF11SLC6A1SLC6A11MEN1KMT2A | |
| SCHEMBL335718 | 0.74 | SLC6A11 (0.46) | KIF11SLC6A1SLC6A11MEN1KMT2A | |
| SCHEMBL8843146 | 0.74 | ALDH1A1 (0.47) | KIF11MEN1KMT2AMAPT | |
| SCHEMBL27081237 | 0.74 | ALDH1A1 (0.47) | KIF11MEN1KMT2AMAPT | |
| SCHEMBL18349840 | 0.73 | HDAC1 (0.41) | KMT2AGAA | |
| SCHEMBL13575117 | 0.73 | SLC6A11 (0.45) | KIF11SLC6A1SLC6A11MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078372-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL | SILENCE THERAPEUTICS GMBH (DE) | 2026-03-19 | — | — | US | disclosed |
| US-20240327843-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL | SILENCE THERAPEUTICS GMBH (DE) | 2024-10-03 | — | — | US | disclosed |
| US-12054717-B2 | Nucleic acids for inhibiting expression of LPA in a cell | SILENCE THERAPEUTICS GMBH (DE) | 2024-08-06 | — | — | US | disclosed |
| US-11987794-B2 | Products and compositions | SILENCE THERAPEUTICS GMBH (DE) | 2024-05-21 | — | — | US | disclosed |
| US-20230272385-A1 | siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND | SILENCE THERAPEUTICS GMBH (DE) | 2023-08-31 | — | — | US | disclosed |
| EP-4219716-A2 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL | Silence Therapeutics GmbH (DE) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219712-A2 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL | Silence Therapeutics GmbH (DE) | 2023-08-02 | — | — | EP | disclosed |
| US-11560563-B2 | SiRNAs with vinylphosphonate at the 5′ end of the antisense strand | SILENCE THERAPEUTICS GMBH (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-3710586-B1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL | SILENCE THERAPEUTICS GMBH (DE) | 2022-11-23 | — | — | EP | disclosed |
| EP-3880818-B1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL | SILENCE THERAPEUTICS GMBH (DE) | 2022-09-28 | — | — | EP | disclosed |
| US-20200063133-A1 | PRODUCTS AND COMPOSITIONS | SILENCE THERAPEUTICS GMBH (DE) | 2020-02-27 | — | — | US | disclosed |
| EP-3607067-A1 | PRODUCTS AND COMPOSITIONS | Silence Therapeutics GmbH (DE) | 2020-02-12 | — | — | EP | disclosed |
| WO-2019193189-A1 | siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS | SILENCE THERAPEUTICS GMBH (DE) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019193144-A1 | siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND | SILENCE THERAPEUTICS GMBH (DE) | 2019-10-10 | — | — | WO | disclosed |
| EP-3549610-A1 | NUCLEIC ACID CONJUGATES | Silence Therapeutics GmbH (DE) | 2019-10-09 | — | — | EP | disclosed |
| EP-3550022-A1 | PRODUCTS AND COMPOSITIONS | Silence Therapeutics GmbH (DE) | 2019-10-09 | — | — | EP | disclosed |
| EP-3550021-A1 | PRODUCTS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF A TARGET GENE | Silence Therapeutics GmbH (DE) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018185252-A1 | NUCLEIC ACID CONJUGATES | SILENCE THERAPEUTICS GMBH (DE) | 2018-10-11 | — | — | WO | disclosed |
| WO-2018185239-A1 | PRODUCTS AND COMPOSITIONS | SILENCE THERAPEUTICS GMBH (DE) | 2018-10-11 | — | — | WO | disclosed |
| WO-2018185253-A1 | LIGAND MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | SILENCE THERAPEUTICS GMBH (DE) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272385-A1 | siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND | RNASE1, DCLRE1B, SNRPE | MMP2 3627/4885MMP9 4036/4885MMP12 2306/4885 |
| US-20260078372-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL | LPAR2, LPCAT1, LPAR1 | MMP2 2797/4885MMP9 572/4885MMP12 1289/4885 |
| US-11560563-B2 | SiRNAs with vinylphosphonate at the 5′ end of the antisense strand | RNASE1, DCLRE1B, SNRPE | MMP2 3577/4885MMP9 3985/4885MMP12 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.